Back

Multi-Omic Factor Analysis uncovers immunological signatures with pathophysiologic and clinical implications in coronary syndromes

Pekayvaz, K.; Losert, C.; Knottenberg, V.; van Blokland, I. V.; Oelen, R.; Groot, H. E.; Benjamins, J. W.; Brambs, S.; Kaiser, R.; Eivers, L.; Polewka, V.; Escaig, R.; Joppich, M.; Janjic, A.; Popp, O.; Petzold, T.; Zimmer, R.; Enard, W.; Saar, K.; Mertins, P.; Huebner, N.; van der Harst, P.; Franke, L. H.; van der Wijst, M. G. P.; Massberg, S.; Heinig, M.; Nicolai, L.; Stark, K.

2023-05-03 cardiovascular medicine
10.1101/2023.05.02.23289392 medRxiv
Show abstract

Acute and chronic coronary syndromes (ACS and CCS) are leading causes of mortality. Inflammation is considered to be a key pathogenic driver, but immune states in humans and their clinical implications remain poorly understood. We hypothesized that Multi-Omic blood analysis combined with Multi-Omic Factor Analysis (MOFA) might uncover hidden sources of variance providing pathophysiological insights linked to clinical needs. Here, we compile a single cell longitudinal dataset of the circulating immune states in ACS & CCS (13x103 clinical & Multi-Omic variables, n=117 subjects, n=838 analyzed samples) from two independent cohorts. Using MOFA, we identify multilayered factors, characterized by distinct classical monocyte and CD4+ & CD8+ T cell states that explain a large proportion of inter-patient variance. Three factors either reflect disease course or predict outcome in coronary syndromes. The diagnostic performance of these factors reaches beyond established biomarkers highlighting the potential use of MOFA as a novel tool for multilayered patient risk stratification.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.